Sutro Biopharma (STRO) Other Non-Current Liabilities (2016 - 2025)

Sutro Biopharma has disclosed Other Non-Current Liabilities across 10 years of filings, most recently posting $1.7 million for Q4 2025.

• Other Non-Current Liabilities for Q4 2025 came in at $1.7 million, changed 0.0% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.7 million (changed 0.0% YoY), and the FY2025 annual result was $1.7 million, changed 0.0% from the prior year.
• Other Non-Current Liabilities came in at $1.7 million for Q4 2025 at Sutro Biopharma, roughly flat from $1.7 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $1.7 million in Q4 2023 to a low of $119000.0 in Q4 2022.
• The 5-year median for Other Non-Current Liabilities is $1.7 million (2023), against an average of $1.1 million.
• Across the five-year window, Other Non-Current Liabilities tumbled 91.16% in 2022 and surged 1323.53% in 2023, its largest moves.
• Sutro Biopharma's Other Non-Current Liabilities stood at $146000.0 in 2021, then dropped by 18.49% to $119000.0 in 2022, then soared by 1323.53% to $1.7 million in 2023, then changed by 0.0% to $1.7 million in 2024, then changed by 0.0% to $1.7 million in 2025.
• The last three Other Non-Current Liabilities figures came in at $1.7 million (Q4 2025), $1.7 million (Q3 2025), and $1.7 million (Q2 2025), per Business Quant data.